Abstract 1830
Background
CART-19 therapy is an immunotherapy treatment based in extracorporeal and synthetic modification of T-lymphocytes from the patient that goes through the therapy. This therapy is used in treatment of haematological cancers like chronic lymphocytic leukaemia (CLL) and acute lymphoblastic leukaemia (ALL) and it can be administered through one aliquot or three aliquots. It is a new therapy recently introduced in cancer treatment which introduces multiple challenges like side effects management. Its main side effect is cytokine release syndrome (CRS). The aim of this study is to compare the side effects observed in patients treated with CART-19 therapy versus side effects described in the literature.
Methods
This is an observational, transversal and retrospective study based in medical records review. The patients included in this study are adults treated with CART-19 therapy in Hospital Clinic Barcelona between January 2017 and April 2019. Data analysis has been done through Excel programme and taking into account clinical variables like: age, diagnosis, arterial pressure, heart rate, number of aliquots and Intensive Care Unit (UCI) requirement.
Results
A total of 27 CART-19 therapies have been administered. 70,4% from infusions have been done in patients with a diagnosis from ALL. The main side effects that have been observed are hypotension in a 29,6%, tachycardia in 22,2% and headache in 11,1%. Fever has been observed in a 85,2% of the infusions and it has appeared in the first 24 hours post-infusion in a 63% of the cases. A high percentage of the infusions have been administered in one aliquot (70,4%). Only in an 29,8% of the cases the patient needed a transfer to an UCI and a 22,2% needed Tocilizumab administration for CRS decrease.
Conclusions
The main conclusion obtained is that observed side effects in patients that have received CART-19 therapy coincide with the ones described in literature, without any new appearance. It is important to emphasise that fever has appeared in patients independent of the number of aliquots received and clinical variables affected. On the other hand, low incidence of neurological and gastrointestinal affections has been observed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract